New lung cancer drug aims to outperform current standard in advanced disease
NCT ID NCT07362459
First seen Jan 24, 2026 · Last updated Apr 30, 2026 · Updated 16 times
Summary
This study tests a new medicine called SCTB14 against the standard drug pembrolizumab as the first treatment for people with advanced non-small cell lung cancer that has not spread to the brain. About 246 adults with a specific tumor marker (TPS ≥10%) will receive either SCTB14 or pembrolizumab, and researchers will compare how long their cancer stays under control. The goal is to see if SCTB14 works better at delaying cancer growth or death.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CARCINOMA NSCLC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Shanghai Chest Hospital
RECRUITINGShanghai, Shanghai Municipality, 200030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.